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Abstract The identification and characterization of the
components of individual signal transduction cascades, and
advances in our understanding on how these biological
signals are integrated in cancer initiation and progression,
have provided new strategies for therapeutic intervention in
solid tumors and hematological malignancies. To this end,
pharmaceutical efforts have been directed to target different
components of the Ras/Raf/MEK and PI3K/PKB pathways.
This review article covers recent salient achievements in the
identification and development of Raf, MEK, and PI3K
inhibitors.
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Abbreviations
HMVEC human dermal microvascular endothelial cells
i.v. intravenous
mTOR mammalian target of rapamycin
PD pharmacodynamic
PK pharmacokinetic
PKB protein kinase B (also known as Akt)
p.o. per os
PTEN phosphatase and tensin homolog deleted on
chromosome 10
RCC renal cell carcinoma
RTKs receptor tyrosine kinases
VEGF vascular endothelial growth factor
Introduction
The growth factor-stimulated Ras/Raf/MEK (Fig. 1) and
PI3K/PKB (Fig. 2) signal transduction pathways have been
demonstrated to play central roles in the biology of human
cancers. Whatever the mechanism, aberrant activation of
these signaling cascades is a frequent event in human
tumors due to their involvement in key biological processes
like cancer cell survival, growth, proliferation, and inva-
sion. Drug discovery activities to control the irregular
activation of these pathways have led to the development of
novel target-based agents for cancer treatment. To this end,
several approaches have been adopted to inhibit or decrease
pathway activity. Much of the original therapeutic efforts
was directed to block receptor tyrosine kinases (RTKs),
which are upstream activators of these pathways (Figs. 1
and 2). The clinical efficacy of antibodies that inhibit
ligand-mediated activation of RTKs—e.g., Herceptin™,
Erbitux™, or Avastin™—or low-molecular mass inhibitors
that target the ATP-binding cleft of these enzymes—e.g.,
Iressa™, Tarceva™, or Tykerb™—have provided proof of
concept of the therapeutic validity of this strategy. Parallel to
the development of RTK inhibitors, pharmaceutical efforts
have also been directed to target some of the cytosolic
moleculesof theRas/Raf/MEK andPI3K//PKB pathways,in
particular protein and lipid kinases. In this review, I will
briefly summarize recent salient medicinal chemistry
achievements in the identification and development of
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Modulators of the Ras/Raf/MEK signaling cascade
The Ras/Raf/MEK pathway (Fig. 1) is activated through the
initial extracellular binding and stimulation of RTKs by
their respective cognate ligands. Upon autophosphorylation
of specific tyrosine residues in the cytosolic domain of
RTKs, the Grb2-Sos complex translocates to the plasma
membrane and converts the inactive Ras guanosine diphos-
phate (GDP) to active Ras guanosine triphosphate (GTP).
The interaction between Grb2 and the activated kinases or
the phosphorylated receptor-associated proteins is mediated
by the SH2 domain of the signaling protein that recognizes
specific phosphotyrosine sequences. Ras undergoes confor-
mational changes upon GTP binding and causes the
recruitment of Raf-1 to the cytoplasmic membrane where
it is phosphorylated by several kinases and simultaneously
diphosphorylated at key residues by protein phosphatase
2B. Activated Raf phosphorylates MEK on two serine
residues in the activation loop, which results in the
activation of this protein kinase. MEK then phosphorylates
and activates ERK, allowing its translocation to the nucleus
where it phosphorylates transcriptional factors permitting
the expression of a variety of genes. As shown in this
section, several components of the Raf/MEK/ERK cascade
represent unique opportunities for cancer treatment [1, 2].
Inhibitors of the kinase activity of Raf
Raf kinases exist as three isoforms A-, B-, and C-Raf. As
previously mentioned, activated Raf phosphorylates and
activates MEK and downstream efforts [3]. B-Raf is one of
the most frequently mutated genes in human cancers, with
an overall frequency of 7–8% [4]. B-Raf mutations have
been found in 27–70% of melanomas, approximately 30%
of papillary thyroid cancers, and 10–15% of colorectal and
ovarian cancers. Among the reported mutations, the most
prominent one results in a change of the Val residue in the
activation loop to Glu [5], leading to a constitutive active
kinase [3]. Accumulating preclinical and clinical studies
have indicated that tumors harboring B-Raf mutations may
exhibit an oncogenic addiction and that this phenotype
presents an unique opportunity for therapeutic interference
by blocking the kinase activity of Raf [6].
Sorafenib (Nexavar™,B A Y4 3 –9006, compound 1,
Fig. 3) is the only Raf kinase modulator to receive
marketing approval—December 2005—for treatment of
advanced renal cell carcinoma (RCC). This biaryl urea
derivative inhibits in in vitro biochemical assays not only
Raf kinase (e.g., IC50=6 nM, 22 nM, and 40 nM for C-Raf,
B-Raf, and B-RafV600E, respectively), but also shows
potent activity for other protein kinases, including the
proangiogenic receptor tyrosine kinases PDFGR-β (IC50=
57 nM), VEGFR-2 (IC50=90 nM), and FGFR-1 (IC50=
580 nM) [7]. The in vivo antitumor activity reported for this
compound is most likely driven by its multikinase
inhibitory profile. In this context, the relative broad-
spectrum in vivo antitumor activity exhibited by sorafenib
in preclinical animal models usually did not correlate with
reduced ERK activation. Thus, tumor stasis was observed
when the compound was administered to mice bearing the
B-RafV600E mutant Colo205 tumor xenograft, but no
significant effect on ERK phosphorylation was detected at
the end of this efficacy study [7].
The resolution of the X-ray structure of the kinase
domain of B-Raf in complex with sorafenib helped to
understand some of the structural features of this kinase and
provided the basis for the rational design of other Raf
kinase modulators [3]. The inhibitor interacts with the ATP-
binding cleft of the enzyme and stabilizes the protein in a
conformation that prevents substrate binding and phosphor-
ylation. In its binding mode, the distal pyridyl group
occupies the ATP-binding pocket and the opposite trifluo-
romethyl-containingphenylmoietyinserts intoa hydrophobic
pocket. The interactions mediated by these groups are
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Fig. 1 Schematic representation of the main cytosolic components of
the Ras/Raf/MEK signal transduction pathway
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urea moiety: one via its amide nitrogen atom to the
carboxylate side chain of the catalytic Glu500 residue and
the second via the carbonyl moiety to the main chain
nitrogen of Asp593 of the DFG moiety. Similar types of
hydrogen bonds have been reported between c-Abl and p38
MAP kinase and their respective inhibitors Gleevec™ and
BIRB-796, probing the importance of these type of
interactions in the unique mechanism of action of these
kinase inhibitors [8–10].
RAF265 (previously known as CHIR-265, compound
2, Fig. 3) is another orally bioavailable Raf modulator
currently being investigated in phase I clinical trials. The
compound inhibits in biochemical assays C-Raf, B-Raf,
B-RafV600E mutant, VEGFR-2, and c-Kit with IC50
values in the low nM range and has shown potent
downregulation of the ERK pathway and tumorigenesis
in relevant in vivo models [11]. PLX4032 (structure not
available), which was identified following a scaffold-
based drug discovery strategy, has also recently started
phase I clinical trials. The compound significantly inhibits
V600E B-Raf (IC50=31 nM) compared with a panel of
over 70 other protein kinases. Its kinase profile translates
into selective antiproliferative activity against Raf- but not
Ras-driven melanoma and colorectal cancer cell lines
(IC50=0.04–0.4 vs 6.5–16 μM against cell lines bearing
mutant Ras). Statistically significant antitumor activity
was observed in mice bearing human colorectal cancer
Colo205 xenografts when given orally at 20 mg/kg per
day, with no effect on body weight and strong inhibition
of pERK as determined by ex vivo analyses of tumor tissue
at the end of the efficacy study. XL281 (structure not
disclosed) is another potent B-Raf, V600E-B-Raf, and C-
Raf inhibitor (IC50=4.5, 6, and 2.5 nM, respectively) that
has initiated phase I clinical trials in 2007. Significant
inhibition of pERK levels was observed in B-Raf-driven
tumor xenograft models with ED50 values ranging from 60
to 90 mg/kg.
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The dual–specificity MEK1 and MEK2 kinases are capable
of phosphorylating both serine/threonine and tyrosine
residues of their physiological substrates ERK1 and
ERK2. The observation that ERK is the only known
MEK substrate and that ERK is commonly activated in
tumor cells has triggered substantial interest in the
identification and development of inhibitors of MEK as a
means to block ERK activation in human cancers [1].
A common feature of the available MEK kinase modu-
lators is their allosteric non-ATP-competitive inhibitory
mechanism. The X-ray structure of the kinase domain of
MEK in complex with one of the early MEK inhibitors—a
derivative of compound 3, Fig. 3—has shown that the
compound did not perturb ATP binding [12]. Instead, the
molecule is bound to a unique, probably exclusive, pocket
adjacent to the Mg/ATP-binding site locking the enzyme in a
catalytically inactive conformation. The recognition of the
amino acids involved in this pocket—Met143, Ile141,
Leu118, and Phe209—and the conformation adopted by
the enzyme upon compound binding may account for the
exclusive target selectivity reported for the current non-ATP-
competitive MEK kinase inhibitors.
CI-1040 (PD184352, compound 3, Fig. 3) was the first
orally active, potent, and selective MEK1/2 inhibitor to enter
clinical trials in cancer patients [13, 14]. Unfortunately, the
compound was determined to have suboptimal human
pharmacokinetic properties—low oral bioavailability and
metabolic instability—and clinical investigations were
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patients with solid tumors [15]. Two second-generation
MEK1- and 2-specific inhibitors—PD0325901 (compound
4, Fig. 3) and ARRY-142886/AZD6244 (compound 5,
Fig. 3)—believed to have addressed some of the pharmaco-
logical deficiencies of CI-1040 have been developed and are
currently undergoing clinical trials [16].
PD0325901 is a structurally related analog of CI-1040.
The modifications introduced in the scaffold resulted in a
significant increase in potency (> 50-fold, IC50=1 nM),
improved oral bioavailability, and better in vivo target
coverage compared to CI-1040. ARRY-142886 is also an
orally bioavailable, potent MEK1/2 inhibitor (IC50=12 nM)
that exploits a similar binding mode as CI-1040 and
PD0325901. Preclinical evaluation of these compounds
showed statistically significant antitumor activity in several
tumor human xenograft models at tolerated doses [2]. The
observed antitumor activity was found to correlate with
suppression of pERK as determined by ex vivo analyses of
tumor tissue. PD0325901 and ARRY-142886/AZD6244 are
currently been evaluated in phase II clinical trials in patients
with solid tumors [1].
The available X-ray structural information has also been
used to design new, non-ATP-competitive MEK inhibitors.
This approach has been nicely illustrated in a recent
publication [17]. The pyridone derivative (compound 6,
Fig. 3) was found to be more potent than CI-1040 (IC50=
4 vs 46 nM, colon26 pERK cellular assay) and more
efficacious in in vivo settings as measured by response rate
as well as tumor growth delay.
In addition to the non-ATP-competitive compounds de-
scribedpreviously,alimitednumberofchemotypeshavebeen
described as classic ATP-MEK1/2-competitive inhibitors.
Representative examples of this class of inhibitors are
cyanoquinoline (compound 7, Fig. 3)[ 18] and resorcyclic
acid (compound 8, Fig. 3)[ 19] derivatives. In addition to
MEK1/2 modulation (e.g., IC50=4 nM for L-783,277) [19],
resorcyclic-based compounds have shown inhibitory activity
a g a i n s tF l t - 3 ,F L T - 1 ,K D R ,P D G F R ,T R K B ,E R K ,a n d
Src. The key pharmacophore in these broad-spectrum
kinase modulators is the enone functionality, which is
involved in the formation of a covalent adduct with Cys-
166. The inherent chemical reactivity of the enone group
to Michael addition poses a major liability to develop
these derivatives as potential new therapeutic agents. For
other examples of competitive and noncompetitive ATP
MEK inhibitors, see [1].
Modulators of the PI3K/PKB signaling cascade
A substantial number of epidemiological and experimental
studies support an important role of the PI3K/PKB
signaling cascade in the biology of human cancer. Thus,
the activation of this pathway (Fig. 2) has been clearly
validated as an essential step for the initiation and
maintenance of the tumorigenic phenotype. Upregulation
can be the result of: (1) constitutively active mutants or
overexpression of some receptor tyrosine kinases (e.g.,
EGFR or ErbB2) leading to constitutive recruitment and
activation of PI3K; (2) amplification and/or overexpression
of the p110α catalytic subunit; (3) presence of activating
mutations in the PIK3CA gene encoding the p110α
catalytic subunit; (4) overexpression of the downstream
kinase PKB (also known as Akt); (5) loss or inactivating
mutation of the tumor suppressor gene phosphatase and
tensin homolog deleted on chromosome 10 (PTEN), a
natural negative regulator of the PI3K pathway; or (6)
constitutive recruitment and activation by mutant forms of
the Ras oncogene. The preceding alterations trigger a
cascade of biological events, from cell growth and
proliferation to survival and migration, that drive tumor
progression, survival, angiogenesis, and metastasis. In
addition to its role in the biology of human tumors, this
pathway also plays a major part in the resistance of tumor
cells to conventional anticancer therapies. Blocking the
PI3K/PKB pathway could therefore simultaneously inhibit
the proliferation and growth of tumor cells and sensitize
them toward programmed cell death. To this end, drug
discovery activities have been directed to identify agents
that effectively and specifically disrupt this pathway in
tumor cells. Herein, the progress in the development of
compounds designed to target PI3K, one of the main
components of the pathway, is briefly reviewed [20, 21].
Inhibitors of the lipid kinase activity of PI3K
3-Phosphorylated inositol lipids are phosphorylated by
members of a family of closely related enzymes known as
PI3Ks. These lipid kinases are ubiquitously expressed in
cells and function as signal transducers downstream of cell
surface receptors. The products of PI3K-catalyzed reac-
tions, phosphatidylinositol 3,4,5-trisphosphate (PtdIns
(3,4,5)P3), phosphoinositidylinositol 3,4-bisphosphate
(PtdIns(3,4)P2), and phosphoinositidylinositol 3-phosphate
(PtdIns(3)P), are second messengers and have central roles
in a number of cellular processes, including cell growth,
differentiation, mobility, proliferation, and survival.
The eight members of the PI3K family have been
classified into three groups based on their primary
sequence, in vitro substrate preference, domain structure,
and mode of regulation. The subject of this section is class I
PI3Ks, which is composed of two subgroups, IA and IB
[22]. The class IA PI3K subgroup consists of there catalytic
subunits, p110α,p 1 1 0 β, and p110δ, that form heterodimers
with one of five regulatory domains: p85α, p85β, p85γ,
Purinergic Signalling (2009) 5:117–125 121p50α, and p55α. As shown in Fig. 2, these PI3Ks are
activated by cell surface receptor tyrosine kinases. The
class IB PI3K consists of one member, a heterodimer of
p110γ and a regulatory p101 domain, that is activated by G
proteins βγ subunits following the stimulation of G
protein-coupled receptors. PI3Ks IA and IB catalyze the
formation of PtdIns(3,4,5)P3, a process that is reversed by
the action of a phosphatase, PTEN.
Two well-known and isoform nonselective PI3K inhib-
itors are the fungal metabolite wortmannin (compound 9,
Fig. 4)[ 23] and LY294002 (compound 10, Fig. 4)[ 24].
Although these two compounds bind to the ATP-binding
cleft of the lipid kinase, they block the enzymatic activity of
PI3K by different mechanisms. Thus, wortmannin is an
irreversible inhibitor (IC50≈ 2 nM) that forms a covalent
bond with a conserved lysine residue in the ATP-binding
cleft of PI3K [25], while LY294002 is a classic ATP-
competitive PI3K inhibitor (IC50=1.40 μM) [24, 26]. In
spite of the crossover inhibition of other lipid and protein
kinases and their unfavorable pharmaceutical properties,
these two compounds have served as powerful research
tools for more than a decade to elucidate the role of PI3Ks
in human tumorigenesis and evaluate the potential utility of
PI3K modulators as cancer therapeutics.
The scaffolds of wortmannin and LY294002 have been
the subject of intense lead optimization efforts to overcome
the pharmaceutical limitations of the parent compounds.
Thus, using wortmannin as a starting point, broad-spectrum
PI3K inhibitors with improved pharmaceutical properties
and therapeutic indexes like PWT-458 (compound 11,
Fig. 4)[ 27] and PX-866 (compound 12, Fig. 4)[ 28, 29]
have been reported. PWT-458 is a PEGylated derivative of
wortmannin that has shown to have a higher therapeutic
index over its parent compound. Upon i.v. administration,
the polyethylene-glycol moiety is cleaved and 17-hydrox-
ywortmannin is released. In vivo antitumor activity has been
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122 Purinergic Signalling (2009) 5:117–125reported in several human xenograft models (e.g., U87MG,
A549, and A498). PX-866, which is a semisynthetic viridin
derivative, potently and irreversibly inhibits PI3Kα, γ,a n dδ
(IC50=5.5, 9.0, and 2.7 nM, respectively), but unlike
wortmannin shows a certain level of selectivity over PI3Kβ
(IC50>300 nM) and higher biological stability. The com-
pound has also shown antitumor activity against several
human solid tumor models (e.g., OvCar-3, HT-29, or A-549)
when used alone (2 mg/kg, p.o.) or in combination with
chemotherapeutic or targeted anticancer agents (e.g.,
paclitaxel or gefitinib). In addition to a decrease in body
weight and leukocytosis, a major toxicity of PX-866
administration to SCID mice was hyperglycemia with
decreased glucose tolerance. These changes were dose
dependent and reversible upon discontinuation of the
drug. PX-866 is expected to enter phase I clinical trials
in 2008.
Similar lead optimization approaches have been used for
LY29002 and derivatives thereof. SF1126 (compound 13,
Fig. 4)[ 30] is a water-soluble prodrug of LY294002. The
compound, which is designed to target specific integrins,
inhibits all paralogs of PI3K (IC50=0.5–5.7 μM) and other
members of the PI3K family, including DNA-PK and
mTOR. It blocks the phosphorylation and activation of
PKB/Akt in cellular settings with IC50 values in the low
μM range (e.g., IC50=2.4 μM, MM.1S). As in the case of
the wortmannin derivatives, SF1126 has demonstrated
significant antitumor activity in several xenograft models
of brain, neuroblastoma, non-small cell lung, prostate,
myeloma, renal, and colon carcinoma. In addition to its
direct activity in cancer cells, microvessel density analysis
of tumor tissue demonstrated that the compound also had
significant antiangiogenic activity in vivo [30]. SF1126 is
currently in phase I clinical trials.
In addition to the efforts made to overcome the pharmaceu-
tical hurdles encountered with wortmannin and LY294002,
high-throughput screening and medicinal chemistry activities
have been utilized to discover pan- or paralog-selective PI3K
inhibitors. Overall, the new generation of PI3K inhibitors have
better pharmacological characteristics than the early com-
pounds as well as improved PI3K selectivity profile. Some of
these compounds are briefly reviewed in the following
paragraphs.
NVP-BEZ235 (compound 14, Fig. 4) is a dual pan-
PI3K/mTOR inhibitor: IC50=4, 76, 7, 5, and 21 nM against
p110α, β, γ, δ, and mTOR, respectively [31, 32]. The
compound exhibits potent antiproliferative activity against
a broad panel of tumor cell lines (e.g., IC50=10 nM,
U87MG cells) by specifically blocking the biological
function of PI3K signaling components (e.g., IC50=10 ±
1 nM, Ser473-PKB/Akt inhibition in U87MG cells). The
antiproliferative activity of this imidazoquinoline derivative
in cellular settings translates well in in vivo models of
human cancer (e.g., U87MG, PC3M, and A549). Thus, the
compound displayed disease stasis or tumor regression
when administered orally—25–50 mg/kg per day—and
enhanced the efficacy of other anticancer agents when used
in in vivo combination studies (e.g., docetaxel or temozo-
lomide). Ex vivo PK/PD analyses of tumor tissues upon
acute dose or after termination of in vivo efficacy studies
showed a time-dependent correlation between compound
concentration and inhibition of PKB/Akt phosphorylation.
NVP-BEZ235 was well tolerated at the efficacious doses
when compared with vehicle-treated animals, with no
significant difference seen in the body weight. Unlike other
modulators of the PI3K/PKB pathway, no elevated blood
glucose levels were observed in the animals treated with
NVP-BEZ235 after in vivo efficacy experiments in mice or
rats. Moreover, no effect on insulin or glucose levels was
reported for NVP-BEZ235 at efficacious doses in a 13-
week rat toxicity study [32]. Phase I trials with this dual
PI3K/mTOR inhibitor were initiated in patients with solid
tumors at the end of 2006.
XL147 and XL765 (structures not disclosed) are also
low-molecular mass PI3K inhibitors in phase I clinical
trials. XL147 is active against class I PI3Ks (IC50=39, 383,
23, and 36 nM for p110α, β, γ, and δ, respectively)
without inhibiting the kinase activity of Vps34 (IC50=
6,975 nM), DNA-PK, or mTOR (IC50 > 15,000 nM) [33,
34]. The compound inhibits PI3K signaling in cultured
tumor cells (IC50=0.40–1 μM, p-Thr308PKB) and blocks
VEGF-induced tubule formation in cellular setting (IC50=
529 nM, HMVEC-L). Oral dosing slows tumor growth or
induces shrinkage in preclinical models of breast, lung,
ovarian, prostate, and glioma tumors. Increased tumor
growth inhibition over the corresponding single agents
was obtained by combining this PI3K inhibitor with
cytotoxic or targeted anticancer agents (e.g., carboplatin,
paclitaxel, or erlotinib). XL765 has similar activity towards
class I PI3K (IC50=39, 113, 9, and 43 nM for p110α, β, γ,
and δ, respectively) as XL147, but, in addition, it also
inhibits DNA-PK (IC50=150 nM) and mTOR (IC50=
157 nM) [35, 36]. As in the case of XL147, tumor growth
is delayed or halted in in vivo efficacy experiments using
suitable xenograft tumor models. Interim analyses of
ongoing phase I studies with these compounds have shown
interpatient variability with terminal half-life values that
ranged from 2.5 to 8 days for XL147 and 2 to 15 h for
XL765. Preliminary signs of exposure-dependent pharma-
codynamic modulation (changes in plasma insulin levels)
were observed at 30 mg/60 mg for XL147 and 15 mg/
30 mg b.i.d. for XL765. Analyses of other surrogate tissues,
including PBMC lysates and hair follicles, for target
modulation are also under investigation.
Imidazopyrimidines and pyridofuropyrimidines with
class I PI3K activity have been disclosed in several
Purinergic Signalling (2009) 5:117–125 123publications. For examples, PI103 (compound 15, Fig. 4)i s
a pan-PI3K inhibitor with enzymatic IC50 values in the
2 nM (PI3Kα) to 15 nM range (PI3Kγ)[ 37, 38]. Despite its
fast in vivo metabolism, the compound, which is rapidly
distributed to tumor tissue, delays the growth of different
subcutaneous human cancer xenografts. Recently, it has
been shown that PI-103 as other pan-PI3K modulators also
inhibits both complexes of mTOR: the rapamycin-sensitive
mTORC1 (IC50=0.02 μM) and the rapamycin-insensitive
mTORC2 (IC50=0.083 μM). The mTOR biochemical
activity was further confirmed in cells, where the com-
pound blocks downstream markers of mTOR signaling
(e.g., phosphorylation of p70 S6 kinase IC50 <0 . 1μM). PI-
103 has shown a significant antitumor activity in human
glioma xenografts with a significant therapeutic window.
The identification and optimization of the preceding PI3K
modulators has certainly benefitted by having early access to
structural information. The resolution of the X-ray structure
of the p110 subunit of PI3Kγ [39, 40], and more recently of
the human p110α/p85α complex [41], has been fundamental
in providing a molecular map of the ATP-binding cleft of
this special family of kinases.
Parallel to the drug discovery efforts to develop pan-
PI3K modulators, there is an increase in interest to identify
inhibitors with some level of selectivity against the different
p110 enzymes. Sequence alignment and homology models
have revealed that some amino acid differences exist
between PI3K members, in particular, at the entrance of
the ATP-binding pocket. Modulating and fine-tuning the
interactions of the modified molecular template with these
amino acids may provide paralog- or mutation-selective
PI3K inhibitors for cancer treatment [42, 43]. To this end,
selectivity trends among compound classes that target PI3K
members have already been identified by extensive bio-
chemical profiling against all the members of this lipid
kinase family [44]. According to these results, inhibitors of
p110β often tend to inhibit also p110δ, whereas inhibitors of
p110α seems to inhibit preferentially p110γ.I n t e r e s t i n g l y ,
and in spite of a clear sequence homology in the kinase
domain, modulators of class I PI3K tend to inhibit also
DNA-PK (e.g., SF1126, XL765). The in vivo exploration—
efficacy and toxicity studies—of compounds with different
selectivity profiles is likely to provide important insights into
the optimal kinase activity profile to exploit for drug
discovery. However, as with any other drug discovery
project, the ultimate proof of the “most desirable lipid kinase
activity profile” will come from clinical trials.
Conclusions and outlook
Rapid progress has occurred in the last few years in the
development of kinase modulators that target different
components of the Ras/Raf/MEK and PI3K/PKB pathways.
As shown in the preceding sections, aberrant activation of
these signaling cascades is a frequent event in human
tumors providing unique opportunities for therapeutic
intervention. Equally important as the epidemiological data,
a better understanding of the different components and their
roles in the Ras/Raf/MEK and PI3K/PKB pathways has
allowed the identification and development of clinical
candidates that control the irregular activation of these
pathways. Medicinal chemists and molecular modelers have
faced the challenge of identifying structural features around
the ATP-binding site of the targeted enzyme to design
specific kinase inhibitors. Despite the lack of complete
specificity, with the exception of the MEK inhibitors that
are among the most selective inhibitors reported to date, the
compounds that have entered clinical trials have shown in
preclinical models significant in vivo antitumor activities in
the absence of limiting toxicities. It is still unclear if the
potential therapeutic benefit and tolerability that direct
inhibition of components of the Ras/Raf/MEK and PI3K/
PKB pathways and potential concomitant inhibition of other
off-targets will be beneficial in the treatment of cancer. We
can only hope that novel and safe targeted anticancer agents
will come from these drug discovery efforts.
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